Aspo Plc Stock Exchange Release June 17, 2014, at 13.00
ASPO TO LIST THE LEIPURIN BUSINESS IN 2014
At the end of 2013, Aspo Plc ("Aspo") expressed its intention to review the preconditions for listing Leipurin Ltd on the NASDAQ OMX Helsinki ("the Helsinki Stock Exchange"). In early 2014, Aspo published a stock exchange release stating that it has strengthened the Board of Directors and active management of Leipurin up to the level of an independent listed company. Preparations to list Leipurin on the Helsinki Stock Exchange have proceeded as planned this spring, and Aspo aims to list Leipurin on the Helsinki Stock Exchange during the fourth quarter of 2014. Aspo will remain a minority shareholder of Leipurin.
Final decisions on the listing process and filing the application for making the shares of Leipurin available for public trading on the stock exchange list will be made during the fourth quarter of 2014 according to Aspo's original schedule, depending on the market situation, the final results of the analysis and other factors associated with the listing decision.
Pohjola Bank Plc is acting as advisor in the analysis process.
Helsinki June 17, 2014
ASPO Plc
Aki Ojanen
CEO
For further information, please contact:
Aki Ojanen, CEO Aspo Plc, +358 9 521 4010, +358 400 106 592, e-mail aki.ojanen (a)aspo.com.
Aspo is a conglomerate that owns and develops business operations in northern Europe and growth markets, focusing on demanding B-to-B customers. Our strong company brands - ESL Shipping, Leipurin, Telko and Kaukomarkkinat - aim to be the market leaders in their sectors. They are responsible for their own operations, customer relationships and the development of these. Together they generate Aspo's goodwill. Aspo's Group structure and business operations are continually developed without any predefined schedules.
DISTRIBUTION:
NASDAQ OMX Helsinki
Key media
www.aspo.com
DISCLAIMER:
The information contained in this stock exchange release shall not constitute an offer to sell or the solicitation of an offer to buy the securities referred to herein. If securities of Leipurin Ltd are subsequently offered and/or listed, any potential decision to invest in the securities, either through subscription or purchase, shall be exclusively based on the prospectus published in connection with such offer and/or listing, and not on this stock exchange release.
In particular, the information contained herein is not for publication or distribution, directly or indirectly, in or into the United States, Canada, Australia, Hong Kong, South Africa, Singapore or Japan. This stock exchange release does not constitute an offer of securities for sale in the United States, nor may the securities be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. The company does not intend to register any portion of the possible offering in the United States or to conduct a public offering of securities in the United States.